17.99
+0.615(+3.54%)
Currency In USD
| Previous Close | 17.37 |
| Open | 17.41 |
| Day High | 18.3 |
| Day Low | 17.24 |
| 52-Week High | 24.35 |
| 52-Week Low | 10.57 |
| Volume | 1.13M |
| Average Volume | 2.18M |
| Market Cap | 2.64B |
| PE | -6.16 |
| EPS | -2.92 |
| Moving Average 50 Days | 16.9 |
| Moving Average 200 Days | 15.01 |
| Change | 0.62 |
If you invested $1000 in Denali Therapeutics Inc. (DNLI) since IPO date, it would be worth $838.46 as of December 14, 2025 at a share price of $17.985. Whereas If you bought $1000 worth of Denali Therapeutics Inc. (DNLI) shares 5 years ago, it would be worth $218.61 as of December 14, 2025 at a share price of $17.985.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 10, 2025 5:14 AM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per sh
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 09, 2025 9:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, p
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
GlobeNewswire Inc.
Dec 04, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales o